Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A novel drug delivery system based on jcv-vlp

a drug delivery system and drug technology, applied in the field of new drug delivery systems, can solve the problems of drug delivery into the central nervous system, drug delivery into the brain, and a great challenge, and achieve the effect of reducing the risk of drug resistan

Inactive Publication Date: 2015-02-12
LIFE SCI INKUBATOR BETRIEBS
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The inventors discovered that the use of VLP as a drug delivery system doesn't compromise the integrity of the BBB, which prevents unwanted substances from entering the CNS and causes brain damage or infection. This information indicates that VLP can be used safely to deliver drugs into the CNS without causing any adverse side effects.

Problems solved by technology

One of the major challenges in modern medicine is the drug delivery.
Drug delivery into the central nervous system (CNS), in particular into the brain, is a great challenge, since the active ingredients at first have to cross the blood-brain barrier and then have to reach the target cells.
Nearly 95% of all effective in vitro drug candidates are not able to pass the BBB in pharmacologically active concentrations.
This includes the risk of adverse side effects.
These nanoparticles often face the problem that they are exported from the CNS by efflux pumps which are expressed in the BBB.
Thus, the protective function of the BBB is put under risk, including the risk of side effects by the entry of unwanted substances or infective entities into the CNS.
This substantial disadvantage is critical for the clinical application of nanoparticles as drug delivery systems.
However, these observations do not provide sound insights into the suitability of VLP, in particular VLP derived from human Polyoma virus and loaded with a cargo, as a drug delivery system for the CNS.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A novel drug delivery system based on jcv-vlp
  • A novel drug delivery system based on jcv-vlp
  • A novel drug delivery system based on jcv-vlp

Examples

Experimental program
Comparison scheme
Effect test

examples

1. VP1-VLPs in Blood-Brain-Barrier (BBB) Model in vitro

[0050]This in vitro experiment shows the ability of the VLPs to cross the BBB in a model system that matches the organisation and properties of the human BBB. In the model system, porcine primary brain endothelial cells (PBCEC) were used which are capable to form the blood-brain-barrier in vitro (Angelow S, Zeni P and Galla H J “Usefulness and limitation of primary cultured porine horoid plexus epithel cells as an in vitro model to study drug transport at the blood-CSF barrier”, Adv Drug Delivery 2004; 56(12): 1859-73).

[0051]PBCEC preparation and cultivation was conducted as described by Rempe et al., BBRC, 2011: Transport of Poly-(n-butylcyano-acrylate) nanoparticles across the blood-brain-barrier in vitro and their influence on barrier integrity.

[0052]The effect of cargo-containing VLPs on the PBCEC in Transwell filter system was explored with the help of relative transendothelial electrical resistance measurement (TEER) (Remp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
pHaaaaaaaaaa
lengthaaaaaaaaaa
Login to View More

Abstract

The invention relates to VLP derived from human polyoma virus loaded with a drug (cargo) as a drug delivery system for transporting said drug into the CNS, in particular of living humans.

Description

FIELD OF THE INVENTION[0001]The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for the use as drug delivery system.BACKGROUND OF THE INVENTION[0002]One of the major challenges in modern medicine is the drug delivery. Drug delivery to a selected site of action (e.g. a selected organ, tissue, cell type, or microcompartment of a cell, etc.) is called drug targeting. By drug targeting an increase of drug concentration at this specific site becomes possible even with a systemic application of the drug. Additionally, contrary to the ordinary systemic application, the rest of the body is not or only to a lower extend exposed to the drug. This leads to a reduced risk of adverse side effects and can allow a higher dosing of the drug. Furthermore, very toxic drugs (e.g. cytotoxic agents used in cancer therapeutics) may be applicable to humans for the first time, since their toxic side effects are minimized by the drug delivery system. In some cas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00C12N15/86C12N7/00
CPCA61K48/0025C12N7/00C12N15/86C12N2710/22041C12N2710/22023C12N2710/22042C12N2710/22022A61K48/00A61K47/50A61P35/00C07K14/025C12N2710/22043C12N2710/22071C12N2710/24023C12N2710/24042C12N2710/24043C12N2710/24071Y02A50/30
Inventor DEMINA, VICTORIAMANNINGA, HEIKOGOTZKE, ARMINGLASSMANN, ALEXANDER
Owner LIFE SCI INKUBATOR BETRIEBS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com